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The burden of diabetes and cardiovascular disease among the Ca-
nadian First Nation population is disproportionately high com-
pared with the general Canadian population. Continuous monitor-
ing of the diabetes epidemic among the Canadian First Nations
population is necessary to inform public health practice. The pur-
pose of the study was to compare the prevalence of diabetes and
cardiometabolic conditions in a Manitoba First Nation between 2
periods.
Methods
Study data were from 2 diabetes screening studies in Sandy Bay
Ojibway First Nation in Manitoba, collected in 2002–2003 and
2011–2012. All adults aged 18 years or older were invited to parti-
cipate in both studies. Crude and sex- and age-standardized pre-
valence of diabetes and cardiometabolic conditions for each peri-
od were estimated and compared with each other by using χ2 tests.
Results
Sex- and age-standardized prevalence of diabetes was estimated at
39.4% (95% confidence interval [CI], 35.1–43.8) in 2002–2003
and was not significantly different (P = .99) in 2011–2012. Sex-
and age-standardized obesity prevalence was significantly lower in
2011–2012, at 48.7% (95% CI, 44.6–52.7), compared with 60.8%
(95% CI, 56.4–65.2) in 2002–2003 (P < .001). However, this find-
ing was accounted for by a lower prevalence of obesity among
men aged 40 to 49 and aged 50 years or older in 2011–2012 com-
pared with 2002–2003. Sex- and age-standardized prevalence of
hypertension (P = .97), abdominal obesity (P = .26), dyslipidemia
(P = .73), and metabolic syndrome (P = .67) were not signific-
antly different between periods. Significantly higher crude preval-
ence of obesity, abdominal obesity, dyslipidemia, and metabolic
syndrome  among  women  compared  with  men  persisted  from
2002–2003 to 2011–2012.
Conclusion
The diabetes epidemic remains a serious problem in this First Na-
tion community. The gap in cardiometabolic burden between men
and women has also persisted.
Introduction
The prevalence of diabetes and cardiovascular disease among the
Canadian First Nation population is disproportionately high com-
pared with the general Canadian population, and the prevalence
has increased in recent years (1–3). Much research on the diabetes
epidemic used administrative data, which are useful for estimating
the burden. However, administrative data are derived from cases
of physician-diagnosed diabetes, which is problematic given the
known significant number of undiagnosed cases. Administrative
data also cannot provide information on comorbid conditions such
as dyslipidemia, obesity, abdominal obesity, and metabolic syn-
drome (4,5)
Another feature of the diabetes epidemic is the geographic hetero-
geneity of burden among First Nations people. Among Canadian
First Nations people living on-reserve, the age-standardized pre-
valence  of  diabetes  was  17.2% in  2008–2009  (6).  In  Saskat-
chewan, the age-standardized prevalence of diabetes among First
Nations people was 20.3% for women and 16.0% for men in 2005
(1). Among urban and rural First Nations from Alberta, the sex-
and age-standardized prevalence of diabetes in 2006 was 11.5%
and 14.7%, respectively (3). In Manitoba, the age-standardized
prevalence in 1998 among First Nations people was 24.9% among
women and 17.0% among men (2). Given the available data, both
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administrative and community-based (7), Manitoba First Nations
people have a high burden of diabetes compared with First Na-
tions people of other provinces. In addition, rates of diabetes vary
significantly by tribal council in Manitoba. The Dakota Ojibway
Tribal Council, of which the study community is a member, has
the highest age- and sex-standardized prevalence of physician-dia-
gnosed diabetes in Manitoba, at 24.9% from 1996–1997 through
1998–1999 (4).
A study completed in 2002–2003 in the Sandy Bay First Nation
indicated that the crude prevalence of diabetes was nearly 30% of
the adult population (5), with an age-standardized rate likely to be
substantially higher. Therefore, the study community is a popula-
tion with a high burden of disease that requires continued monitor-
ing. The purpose of this study is to describe the burden of dia-
betes and other cardiometabolic conditions in a Manitoba First Na-




The study community is Sandy Bay Ojibway First Nation, located
in southwest Manitoba, approximately 200 kilometers northwest
of Winnipeg. This community is accessible year round by road.
The total on-reserve population in 2011 was approximately 4,100
people, 50% of whom are younger than 19 years.
Design
Data from the 2002–2003 and 2011–2012 diabetes screening stud-
ies were included in the repeated cross-sectional design. Details
about the 2002–2003 screening study can be found elsewhere (5).
Briefly, Sandy Bay First Nation invited researchers to conduct a
diabetes screening study. Fasting blood samples were taken, and
anthropometric and questionnaire data were collected. Data collec-
tion occurred between October 2002 and December 2003. The
second cross-sectional study, conducted between July 2011 and
June 2012, also took fasting blood samples and collected anthro-
pometric and questionnaire data. Both studies were approved by
the University of Manitoba Health Research Ethics Board.
The study used a community-based participatory framework (8).
The community identified the problem and sought out university
researchers. A diabetes advisory group, including members from
the Health Centre, community members, and university research-
ers, has overseen all aspects of the studies since 2002. The com-
munity uses the results when attending meetings with government
to provide evidence for action.
Sampling
All adults who were aged 18 years or older and not pregnant were
invited to participate in both study periods (ie, study sample was a
convenience sample). Participants had to be registered members of
Sandy Bay Ojibway First Nation or a registered member of anoth-
er First Nation but living in Sandy Bay. Recruitment was conduc-
ted through advertisement at the Community Health Centre and
via a local radio station, word of mouth, and home visits from
community research assistants. Transportation was offered to all
participants.
Outcomes
Venous blood samples were drawn by a registered nurse after a
minimum 12-hour  fast.  Methods  for  measurement  of  glucose,
hemoglobin A1c (HbA1c), triglycerides, and high-density lipopro-
tein (HDL) cholesterol have been described previously (5). Blood
pressure was assessed by trained research assistants using an auto-
mated blood pressure monitor  (Omron Corporation). At least 2
blood pressure readings were taken and averaged. Anthropometric
measures  — height,  weight,  and waist  circumference — were
taken using standard techniques (9).
Diabetes was defined by self-report, currently taking an oral hy-
poglycemic medication, or having a fasting blood glucose of 7.0
mmol/L or higher (10,11). Impaired fasting glucose (IFG) was
defined as a fasting blood glucose between 6.1 and 6.9 mmol/L
(12). Obesity was defined as a body mass index (BMI, measured
as weight in kilograms divided by the square of height in meters)
of 30 kg/m2 or higher (13). Hypertension was defined as a previ-
ous diagnosis of hypertension or a systolic blood pressure (SBP)
higher than 140 mm Hg or diastolic blood pressure (DBP) higher
than 90 mm Hg; for participants with diabetes, hypertension was
defined as an SBP of 130 mm Hg or more or a DBP of 80 mm Hg
or more (10,11). Dyslipidemia was defined as a fasting plasma
triglyceride of 1.7 mmol/L or higher and a fasting plasma HDL of
less than 1.03 mmol/L (for men) or a plasma HDL of less than
1.30 mmol/L (for women) (14). Metabolic syndrome was defined
as meeting 3 or more of the following criteria: waist circumfer-
ence of 102 cm or more for men and of 88 cm or more for women,
a fasting blood glucose of 5.6 mmol/L or more (or previous dia-
betes diagnosis),  a  fasting triglyceride level  of  1.7 mmol/L or
more, an HDL cholesterol level of less than 1.03 mmol/L for men
or less than 1.30 mmol/L for women, and a blood pressure of 130/
85 mm Hg or more or a previous diagnosis of hypertension (14).
Statistical analysis
Sociodemographic characteristics, such as age, sex, highest level
of education, and employment (either full-time or part-time), are
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reported for each of the samples using frequencies, means, and
standard deviations (SDs). Differences in mean age between peri-
ods were tested using an independent sample t test. Differences in
proportions of other characteristics between periods were tested
using χ2 test.
Sex- and age-stratified crude prevalence of diabetes and cardi-
ometabolic conditions were estimated for each period. Sex- and
age-standardized prevalence were also estimated for each cardi-
ometabolic condition, using the 2010 Canadian population estim-
ates, participants being aged 18 years or older (15), and the direct
method of standardization. Age groups were 18 to 29, 30 to 39, 40
to 49, and 50 years or older (5). To determine differences in dia-
betes and cardiometabolic conditions between the 2 periods, non-
linear mixed-model with random intercept were used to account
for dependency in the data. However, mixed models did not con-
verge because of the limited number of participants with repeated
measures (n = 171). As a result, differences in sex- and age-stand-
ardized prevalence of each cardiometabolic condition between
periods were determined using χ2 tests. Sex differences in crude
prevalence of each respective cardiometabolic condition for each
period were also assessed using χ2 test. Differences in prevalence
between periods were further explored to determine differences in
odds of a condition by using logistic regression adjusting for age
group, sex, and other relevant conditions. Analyses were conduc-
ted for separate age groups when appropriate.
To further explore differences over time in the burden of diabetes,
we also tested for differences in fasting blood glucose, HbA1c,
and age at diagnosis between periods. Generalized linear models
with gamma distribution to account for a skewed distribution were
used. Analyses for age at diagnosis were conducted only for those
with diabetes. Control variables were age group, sex, and pres-
ence of diabetes (for fasting blood glucose and HbA1c). Interac-
tion effects were also explored, and stratified analyses were con-
ducted to understand changes in health status between the periods.
All statistical analyses were conducted using SPSS version 22
(IBM Corporation). All tests of significance were conducted us-
ing an α level of .05.
Results
A total of 482 community members (44% of the eligible popula-
tion) participated in 2002–2003. The sample was representative of
the community according to age, sex, and employment status (5).
The 2011–2012 sample totaled 596 participants, or 28% of the eli-
gible population (Table 1). The percentage of the eligible popula-
tion was equal for men and women (27.8% for men and 27.3% for
women). The 2011–2012 sample was representative of the popula-
tion  according  to  age  group  and  sex.  The  mean  age  of  the
2011–2012 sample was significantly younger than the mean age of
the 2002–2003 sample (P = .007); both samples had a similar pro-
portion of men and women (P = .13). The 2011–2012 sample was
more  highly  educated  than  the  2002–2003  sample,  but  the
2011–2012 sample had a significantly lower employment rate than
the 2002–2003 sample (Table 1).
Sex- and age-specific prevalence of diabetes and other cardiometa-
bolic conditions are reported in Table 2. The crude prevalence of
diabetes was 29.0% (95% confidence interval [CI], 25.0%–33.1%)
in 2002–2003 and 25.9% (95% CI, 22.4%–29.4%) in 2011–2012.
An additional 6.2% (95% CI, 4.1%–8.4%) had IFG in 2002–2003
and 6.1% (95% CI,  4.2%–8.0%) in 2011–2012.  Sex- and age-
standardized  prevalence  of  diabetes  was  39.4%  (95%  CI,
35.1%–43.8%) in 2002–2003 and 39.2% (95% CI, 35.3%–43.1%)
in 2011–2012 (Figure); the change between periods was not signi-
ficant (P = .99). During both study periods, the crude diabetes pre-
valence was higher among women than men, but the difference
was not significant. In 2002–2003, 7.3% (95% CI, 5.0%–9.6%) of
the sample had undiagnosed diabetes; in 2011–2012, 6.1% (95%
CI, 4.2%–8.0%) of the total sample had undiagnosed diabetes. Of
those  with  diabetes,  25.4%  (95%  CI,  18.1%–32.7%)  met  the
HbA1c target of <7.0% (10) in 2002–2003, and 26.0% (95% CI,
19.1%–32.9%) met the target in 2011–2012.
Figure. Sex- and age-standardized prevalence of diabetes and cardiometabolic
conditions  in  Sandy  Bay  First  Nation  population,  2002–2003  and
2011–2012.
 
Among participants with diabetes, including those with newly dia-
gnosed diabetes, there was not a significant difference in age at
diagnosis between periods (P = .15), independent of age group and
sex. In 2002–2003, the mean age at diagnosis was 38.6 years (SD,
11.6  y)  for  men  and  38.0  years  (SD,  12.7  y)  for  women;  in
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2011–2012, the mean ages were 37.9 years (SD, 10.9 y) for men
and 37.0 years (SD, 11.2 y) for women. Fasting blood glucose was
significantly higher (P < .001) among participants without dia-
betes in 2011–2012, at 5.39 mmol/L (SD, 0.49 mmol/L), com-
pared with 5.21 mmol/L (SD, 0.58 mmol/L) in 2002–2003, inde-
pendent of age group or sex. HbA1c was significantly higher (P <
.001) among participants without diabetes in 2011–2012 (5.78%
[SD, 0.34%]) compared with 2002–2003 (5.60% [SD, 0.42%]), in-
dependent of age group or sex.
The crude prevalence of hypertension in 2002–2003 was 40.8%
and 39.4% in 2011–2012. Crude prevalence was not significantly
different  between  men  and  women  in  2002–2003  (P  =  .14).
However, the crude prevalence of hypertension was significantly
higher among men than women in 2011–2012 (P = .015). The sex-
and age-standardized prevalence of hypertension was 52.4% in
2002–2003 and 53.1% in  2011–2012 (Figure);  the  prevalence
between periods was not significantly different (P = .97). Undia-
gnosed  hypertension  was  found  in  13.6%  of  the  sample  in
2002–2003 and in 18.6% in 2011–2012. Among participants with
diabetes, 82.2% had hypertension and 31.0% had undiagnosed hy-
pertension in 2002–2003, and 78.0% had hypertension and 34.4%
had undiagnosed hypertension in 2011–2012.
The crude prevalence of obesity was 56.6% in 2002–2003 and
47.4% in 2011–2012. During both periods, the sex-specific crude
prevalence was significantly higher among women than men (P <
.001 for  both).  The sex-  and age-standardized prevalence was
60.8% in 2002–2003 and 48.6% in 2011–2012 (Figure). The sex-
and  age-standardized  prevalence  of  obesity  was  significantly
lower in 2011–2012 (P < .001). Differences in crude prevalence
between periods varied according to age and sex (Table 2). For ex-
ample,  among  men  aged  40  to  49  years,  crude  prevalence  of
obesity was 62.5% in 2002–2003 and 27.3% in 2011–2012. Lo-
gistic regression models confirmed a significantly lower odds of
obesity in 2011–2012 compared with 2002–2003 among men aged
40–49 and ≥50 years (data not shown). The models for men were
further adjusted by diabetes status, because diabetes can result in
weight loss, as well as hypertension. However, these adjustments
did  not  change  the  significant  difference  in  odds  of  obesity
between time periods among men in either age group.
The  crude  prevalence  of  abdominal  obesity  was  67.4%  in
2002–2003 and 64.6% in 2011–2012. The sex- and age-standard-
ized  prevalence  was  73.8%  in  2002–2003  and  69.1%  in
2011–2012 (Figure), which was not significantly different (P =
.26). Sex-specific crude prevalence was 53.1% for men and 81.0%
for women in 2002–2003 and 47.6% for men and 83.0% for wo-
men in 2011–2012. Again, prevalence was significantly higher
among women than men in each period (P < .001 for both).
The crude prevalence of dyslipidemia in 2002–2003 was 31.1%
and 25.4% in 2011–2012. The sex-specific prevalence was signi-
ficantly  higher  among  women  than  men  in  each  period
(2002–2003, P = .007; 2011–2012, P = .003). The sex- and age-
standardized prevalence was 32.6% in 2002–2003 and 30.4% in
2011–2012 (Figure) and not significantly different (P = .73).
The crude prevalence of metabolic syndrome in 2002–2003 was
54.3% and 49.5% in 2011–2012. The sex-specific prevalence was
higher for women compared with men in each period (2002–2003,
P = .003; 2011–2012, P = .002). The sex- and age-standardized
prevalence of metabolic syndrome was 62.5% in 2002–2003 and
59.9% in 2011–2012 (Figure) and not significantly different (P =
.67).
Discussion
Overall,  few substantial  changes  at  the  population  level  were
found for cardiometabolic burden from 2002–2003 to 2011–2012
in this Canadian First Nation community. The sex- and age-stand-
ardized  diabetes  prevalence  was  not  significantly  different
between periods. It is difficult to make statements about the tra-
jectory of the diabetes epidemic on the basis  of only 2 points.
However, the absolute burden of disease, with a sex- and age-
standardized diabetes prevalence at 39.2% in 2011–2012, is con-
siderable. Another feature of the epidemic in this community was
the adverse changes in fasting glucose among those without dia-
betes. This finding is concerning because it may indicate a de-
crease in health status among those without diabetes,  many of
whom are young. An additional note on the diabetes epidemic in
Sandy Bay is the persistence of a high rate of undiagnosed dia-
betes and hypertension and young age at diagnosis. Diagnosis of
diabetes is critical in managing blood glucose and in preventing
and delaying complications (16), particularly among young people
when risk of complications is greater (17).
The implications of significant differences in sociodemographic
factors between the 2 study periods are difficult to interpret. Crude
rates of diabetes and most conditions were lower in 2011–2012
because of the younger age of the study population relative to
2002–2003. However sex- and age-standardized rates were simil-
ar. Although educational levels increased, translation into greater
employment has not occurred because of limited opportunities in
the community and surrounding area. Therefore, social conditions
likely remain a contributor to cardiometabolic outcomes in the
study community.
Sex-specific patterns are another feature of the epidemic. The liter-
ature has consistently reported higher rates of diabetes among First
Nations women than among First Nations men (1–3). In contrast
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to the findings published in the literature (1–3), we found that the
prevalence of diabetes was not significantly different between men
and women in either period. This may be a feature of a more ad-
vanced epidemic, given the reported reduction in the diabetes gap
between men and women over time in Saskatchewan (1). Simil-
arly, an increasing incidence of diabetes over time for First Na-
tions men compared with a plateau for First Nations women in
Manitoba during the 1990s was reported (2). The higher preval-
ence of other cardiometabolic conditions found among women
than among men in this study may partially explain the higher risk
associated with diabetes on cardiovascular outcomes for women
reported in other populations (18). This explanation is also con-
sistent with previous reports suggesting that women experience
more pronounced adverse changes in lipid profile in response to
diabetes compared with men (19,20). This sex difference may also
partially explain the larger gap in rates of cardiovascular mortality
observed between Canadian First Nations women and non-First
Nations women compared with their male counterparts (21).
Although the lower prevalence of obesity in 2011–2012 compared
with 2002–2003 was encouraging, this finding was mostly accoun-
ted for by the lower prevalence among middle-aged men. This dif-
ference over time among middle-aged men was not accounted for
by diabetes  or  hypertension.  The  lower  prevalence  of  obesity
among men aged 40 to 49 also coincided with a lower prevalence
of dyslipidemia and metabolic syndrome, which is not surprising
given their known associations. However, prevalence of diabetes
and hypertension were not lower in 2011–2012 in this age group;
therefore, this apparent population improvement should be inter-
preted with caution.
There are several strengths and limitations of this study. First, it
was conducted using a community-based participatory framework.
The researchers  will  continue to  work with  the  community  to
translate  the  findings  and support  policy  changes  at  the  com-
munity level.  Second, this study provides a rich description of
changes, or lack thereof, of an important public health problem in
this population, which cannot be ascertained using administrative
data. Sample size, issues of sample dependence, and multiple com-
parisons may be considered limitations.
Primary care services need to be strengthened and additional pub-
lic health efforts are needed to address the diabetes and cardi-
ometabolic burden in this community. The burden of disease is
troublesome, given the early age at diagnosis of diabetes and dia-
betes-related conditions. Of particular concern is the higher pre-
valence of several of these conditions among women in the com-
munity. This study provides a benchmark for the community to
use when planning, implementing, and evaluating future interven-
tions.
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Tables
Table 1. Chracteristics of Participants in a Cross-Sectional Study of Diabetes and Cardiometabolic Conditions, Sandy Bay First Na-
tion Residentsa, 2002–2003 and 2011–2012
Characteristic 2002–2003 (n = 482) 2011–2012 (n = 596) P Valueb
Mean age, y (SD) 37.8 (12.3) 35.7 (12.9) .007
Age group, y
18–29 142 (29.5) 237 (39.8)
.001
30–39 144 (29.9) 127 (21.3)
40–49 108 (22.4) 134 (22.5)
≥50 88 (18.3) 98 (16.4)
Sex
Male 230 (47.7) 312 (52.3)
.13
Female 252 (52.3) 284 (47.7)
Education levelc
<grade 9 248 (53.0) 159 (27.2)
<.001
≥grade 9 220 (47.0) 426 (72.8)
Employed
Yes 137 (28.8) 123 (20.6)
.002
No 338 (71.2) 473 (79.4)
Abbreviation: SD, standard deviation.
a Data presented as no. (%), unless otherwise indicated.
b P value for mean age calculated using independent sample t test for difference between cross-sectional samples; all other P values calculated using χ2 test of in-
dependence cross-sectional samples.
c Based on median split in 2003 sample.
PREVENTING CHRONIC DISEASE VOLUME 11, E198
PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY   NOVEMBER 2014
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
www.cdc.gov/pcd/issues/2014/14_0334.htm • Centers for Disease Control and Prevention       7
Table 2. Crude Sex- and Age-Specific Prevalence of Cardiometabolic Conditions Among Sandy Bay First Nation Residents,
2002–2003 and 2011–2012
Disease/Conditiona Age group, y
Men, % (95% CI) Women, % (95% CI)
2002–2003 2011–2012 2002–2003 2011–2012
Diabetes (n = 1,077) All ages 27.0 (21.2–32.7) 24.8 (20.0–29.6) 31.0 (25.2–36.7) 27.1 (21.9–32.3)
18–29 8.2 (1.9–14.5) 5.2 (1.4–8.9) 15.9 (7.3–24.6) 9.8 (4.0–15.6)
30–39 23.1 (12.8–33.3) 25.4 (14.3–36.5) 20.3 (11.4–29.1) 23.9 (13.7–34.1)
40–49 36.7 (23.2–50.2) 33.8 (22.6–45.1) 33.9 (21.8–46.0) 31.8 (20.6–43.1)
≥50 53.5 (38.6–68.4) 65.3 (52.0–78.6) 68.9 (55.4–82.4) 61.2 (47.6–74.9)
Hypertension (n = 1,063) All ages 37.3 (31.0–43.6) 44.0 (38.5–49.5) 44.0 (37.8–50.3) 34.3 (28.7–39.8)
18–29 9.6 (2.8–16.3) 22.4 (15.3–29.4) 26.5 (16.0–37.0) 14.9 (7.9–21.8)
30–39 38.5 (26.6–50.3) 50.0 (37.3–62.7) 32.1 (21.7–42.4) 31.3 (20.2–42.5)
40–49 47.9 (33.8–62.0) 51.5 (39.5–63.6) 54.5 (41.4–67.7) 39.4 (27.6–51.2)
≥50 71.4 (57.8–85.1) 85.7 (75.9–95.5) 81.0 (69.1–92.8) 71.4 (58.8–84.1)
Obesity (n = 1,061) All ages 47.6 (41.1–54.1) 35.6 (30.3–40.9) 65.1 (59.1–71.2) 60.2 (54.5–65.9)
18–29 35.6 (24.6–46.6) 36.6 (28.4–44.7) 61.8 (50.2–73.3) 51.0 (41.3–60.7)
30–39 43.1 (31.0–55.1) 41.7 (29.2–54.1) 61.5 (50.7–72.3) 67.2 (55.9–78.4)
40–49 62.5 (48.8–76.2) 27.3 (16.5–38.0) 64.8 (52.1–77.6) 66.7 (55.3–78.0)
≥50 58.5 (43.5–73.6) 36.7 (23.2–50.2) 78.0 (65.4–90.7) 61.2 (47.6–74.9)
Dyslipidemia (n = 1,077)a All ages 25.2 (19.6–30.8) 20.3 (15.8–24.7) 36.5 (30.6–42.5) 31.0 (25.6–36.4)
18–29 16.4 (7.9–24.9) 15.6 (9.4–21.7) 27.5 (17.0–38.1) 18.6 (11.1–26.2)
30–39 29.2 (18.2–40.3) 33.9 (21.8–46.0) 35.4 (24.9–46.0) 34.3 (23.0–45.7)
40–49 36.7 (23.2–50.2) 17.6 (8.6–26.7) 39.0 (26.5–51.4) 28.8 (17.9–39.7)
≥50 20.9 (8.8–33.1) 20.4 (9.1–31.7) 48.9 (34.3–63.5) 55.1 (41.2–69.0)
Metabolic syndrome (n = 1,050) All ages 47.3 (40.8–53.9) 43.5 (37.9–49.0) 61.0 (54.8–67.2) 56.0 (50.2–61.8)
18–29 28.8 (18.4–39.2) 29.5 (21.8–37.3) 45.5 (33.4–57.5) 34.0 (24.7–43.3)
30–39 40.0 (28.1–51.9) 54.2 (41.5–66.9) 55.1 (44.1–66.2) 58.2 (46.4–70.0)
40–49 68.1 (54.8–81.4) 43.9 (32.0–55.9) 69.2 (56.7–81.8) 63.6 (52.0–75.2)
≥50 68.3 (54.0–82.5) 67.3 (54.2–80.5) 87.5 (77.3–97.7) 87.8 (78.6–96.9)
Abbreviation: CI, confidence interval.
a Represents the sample, for both periods combined, for which data were available for each disease/condition. This value includes repeated measures.
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